Date: 2014-11-18
Type of information: R&D agreement
Compound:
Company: Ipsen (France) Salk Institute (USA)
Therapeutic area: Cancer - Oncology - Neurodegenerative diseases
Type agreement: R&D
Action mechanism:
Disease:
Details: * On July 12, 2011, Ipsen and the Salk Institute have announced that they are renewing the Ipsen Life Sciences Program at The Salk Institute. The mission of the partnership is to advance knowledge in the field of proliferative and degenerative diseases through fundamental and applied biology research. The Ipsen Life Sciences Program led by the Salk Institute’s Inder Verma, Ph.D., Irwin and Joan Jacobs Chair in Exemplary Science will for a period of three years, sponsor four research programs through targeted and innovation grants. Ipsen will provide funding for targeted research programs carried out at The Salk Institute by researchers on novel therapeutic concepts for the treatment of pituitary adenomas, cancer and neurodegenerative diseases. Innovation grants will fund the exploration of advanced scientific concepts.
Over the last 3 years, the partnership between the Salk Institute and Ipsen has delivered significant scientific advances in the cancer field such as the development of biological models mimicking human cancerous processes as well as identification of specific cells driving tumor growth. In addition, the development of stem cells technology has opened up promising new vistas of research in neurodegenerative diseases.
Financial terms:
Latest news: * On November 18, 2014, Ipsen and the Salk Institute for Biological Studies (Salk Institute) announced that they have agreed to renew their collaboration in medical sciences for another three years. The common objective for Ipsen and the Salk Institute is to achieve critical insights in the understanding of human diseases so as to develop new therapies for the treatment of patients
afflicted with serious medical conditions. In the next three years, Salk Institute’s Professor Inder Verma, Ph.D., Irwin and John Jacobs Chair in Exemplary Science, will carry out research under the renewed Salk-Ipsen Life Sciences Program, together with Fred Gage, Ph.D., Vi and John Adler Chair for Research on Age-Related Neurodegenerative Disease, and Ron Evans, Ph.D., Professor, March of Dimes Chair in Molecular and Developmental Biology.
The 2011-2014 collaboration led to deeper knowledge of how modified viruses can induce laboratory tumour models to better understand human cancer, how human induced pluripotent stem cell neurons may be used to study neurodegenerative diseases, and how tumour cells interact with their tissue microenvironment. The continuing research in each of these programs, sponsored through ongoing innovation and targeted grants to Salk Institute, is expected to deliver further insights enabling progress in development of therapeutics to address patient needs in oncology, endocrinology and neurodegenerative diseases.
